Madison NORML

Accomplia, aka rimonabant, has been linked to serious psychiatric reactions, including suicide, aggression, anxiety, depression, and sleep disorders.

Medical cannabis experts anticipated these problems as rimonabant works by blocking our cannabinoid receptors, which are essential to the proper function of our bodies, and that the problems caused by Accomplia are commonly treated with cannabis.

Source: Forbes.com Health Highlights: Oct. 24, 2008 click here

(snip)

Sales of Anti-Obesity Drug Acomplia Suspended in Europe

Hours after European health authorities warned doctors to stop prescribing the anti-obesity drug Acomplia (rimonabant), the drug's maker announced Thursday that it was suspending European sales, the Associated Press reported.

Earlier, the European Medicines Agency (EMEA) warned that patients who took the drug had approximately twice the risk of serious psychiatric problems.

Maker Sanofi-Aventis said Acomplia has been sold in 18 European Union countries since 2006. The company said it would immediately begin talks with nations outside the EU to suspend sales in those countries as well, the AP reported.

The U.S. Food and Drug Administration last year refused to approve the drug, citing company studies that associated it with depression, anxiety and stress disorders.

In its warning Thursday, the EMEA said people taking the drug didn't need to immediately stop using it, but should consult their doctor. It also urged physicians to review the cases of anyone taking the drug.

There have been ongoing concerns about the risks of depression and suicide among patients taking Acomplia. Last year, the EMEA said the drug may be unsafe for patients also taking antidepressants, BBC News reported.

At that time, doctors were also advised not to give the drug to people with a history of major depression, and to watch for new symptoms of depression in people already taking the drug.

Between June and August 2008, BBC News reported, there were five suicides among clinical trial participants taking the drug, compared to one suicide among participants taking a placebo.

(snip)